DelveInsight Sitemap

All Report Categories
ID Categories Action
1 Market Insight See Reports See Sample Page
2 Epidemiology Insight See Reports See Sample Page
3 Pipeline Insight See Reports See Sample Page
4 Drug Insight See Reports See Sample Page
5 Mechanism of Action Insight See Reports See Sample Page
6 Drug API Insight See Reports See Sample Page
7 Competitive Landscape See Reports See Sample Page
8 Specialised Reports See Reports See Sample Page
9 API Manufacturers, Marketed and Phase III Drugs Landscape See Reports See Sample Page
10 Biosimilars See Reports See Sample Page
11 Vaccines See Reports See Sample Page
12 Drug Insight and Market Forecast See Reports See Sample Page
13 Country Healthcare See Reports See Sample Page
All Report Infographics
All Static Pages
ID Pages Priority Action
1 Home Page 1.0 Visit Page
2 Blog Page 0.9 Visit Page
3 About Us 0.9 Visit Page
4 Pipeline Assessment Services 0.8 Visit Page
5 BIO Us Event 0.8 Visit Page
6 BIO Taiwan Event Page 0.8 Visit Page
7 BIO Pharm Event 2019 0.8 Visit Page
8 BIO Japan 2019 0.8 Visit Page
9 Bio Europe 2019 Event 0.8 Visit Page
10 PharmDelve 0.9 Visit Page
11 Contact Us 0.7 Visit Page
12 DelveInsight Register 0.9 Visit Page
13 Whitepaper/Newsletter 0.9 Visit Page
14 Press Release 0.9 Visit Page
15 case study 0.9 Visit Page
16 Careers 0.9 Visit Page
17 Events 0.9 Visit Page
18 Market Research 0.9 Visit Page
19 Report Sore 0.9 Visit Page
20 Consulting 0.9 Visit Page
21 Case Study Asset Prioritization 0.8 Visit Page
22 Case Study : Out Licensing Opportunity - Success Stories 0.8 Visit Page
23 Case Study : In Licensing Opportunity - Success Stories 0.8 Visit Page
24 Case Study : Go to Market Strategy - Success Stories 0.8 Visit Page
25 Launch Landscape Analysis 0.8 Visit Page
26 Case Study : Product Assessment - Success Stories 0.8 Visit Page
27 Asset Prioritizaton Services 0.8 Visit Page
28 business development services 0.8 Visit Page
29 Competitive Intelligence Services 0.8 Visit Page
30 Licensing Services 0.8 Visit Page
31 Merger and Acquisition 0.8 Visit Page
32 Partner Identification Services 0.8 Visit Page
33 Competitive Benchmarking Services 0.8 Visit Page
34 Pharmaceutical Portfolio Management Solutions 0.8 Visit Page
35 R&D Analysis 0.8 Visit Page
36 Market Assessment Services 0.8 Visit Page
37 Regulatory Analysis Services 0.8 Visit Page
38 Due Diligence Services 0.8 Visit Page
39 Terms and Conditions 0.7 Visit Page
40 Privacy Policy 0.7 Visit Page
41 Case study - portfolio management 0.8 Visit Page
42 Case Study - Pipeline Assessment Consulting Services 0.9 Visit Page
43 Case Study - Due Diligence Consulting Services 0.9 Visit Page
44 Event - Bio Asia-Taiwan 2019 0.6 Visit Page
45 Case Study - Partner Identification Consulting Services 0.8 Visit Page
46 Case Study - Regulatory Analysis Consulting Services 0.8 Visit Page
47 COVID 19 0.9 Visit Page
48 Sitemap 0.9 Visit Page
49 DUPHAT CONFERENCE 0.9 Visit Page
50 Mergers and Acquisitions Case study 0.9 Visit Page
51 Case study - Competitive Benchmarking 0.9 Visit Page
52 Case Study - R&D Analysis 0.8 Visit Page
53 CEO Message on CoronaVirus 0.9 Visit Page
54 Specialised Reports 0.9 Visit Page
55 Pipeline Insight 0.9 Visit Page
56 Mechanism of Action 0.9 Visit Page
57 Epidemiology Insight 0.9 Visit Page
58 Drug Insight 0.9 Visit Page
59 Drug API Insight 0.9 Visit Page
60 Competitive Landscape 0.9 Visit Page
61 Global API Manufacturers, Marketed and Phase III Drugs Landscape 0.9 Visit Page
62 ASCO Conference 0.9 Visit Page
63 ASCO Day 1 0.9 Visit Page
64 Day 2 ASCO 0.9 Visit Page
65 ASCO All 0.9 Visit Page
66 404 0.6 Visit Page
67 Day 3 ASCO 0.9 Visit Page
68 BIO EUROPE WINTER 2019 0.9 Visit Page
69 BIO Japan 2020 0.7 Visit Page
70 Advance Search 0.7 Visit Page
71 infographics 0.9 Visit Page
72 ESMO Conference 2020 0.9 Visit Page
73 All ESMO Conference 2020 0.9 Visit Page
74 Vaccines - Sitemap 0.9 Visit Page
75 Drug Insight and Market Forecast 0.7 Visit Page
76 Biosimilars Vaccines 0.7 Visit Page
77 Market Insight 0.9 Visit Page
78 Country Healthcare Sitemap 0.9 Visit Page
79 Market Size & Forecast Assessment 0.9 Visit Page
80 Competitive Landscape Assessment 0.8 Visit Page
81 Market & Competitive Assessment 0.8 Visit Page
82 Medical Device 0.9 Visit Page
83 BIO Digital 2021 | BIO International Convention Digital 2021 0.8 Visit Page
84 ASCO Conference 2021 0.8 Visit Page
85 ASCO 2021 All 0.9 Visit Page
86 Sitemap - Cardiovascular Diseases 0.9 Visit Page
87 Sitemap - Cell and Gene Therapy 0.9 Visit Page
88 Sitemap - Central Nervous System 0.9 Visit Page
89 Sitemap - Dental and Oral Health 0.8 Visit Page
90 Sitemap - Dermatology 0.9 Visit Page
91 Sitemap - Endocrinology and Metabolic Disorders 0.9 Visit Page
92 Sitemap - Gastroenterology 0.9 Visit Page
93 Sitemap - Genetic Disorders 0.9 Visit Page
94 Sitemap - Genito Urinary System and Sex Hormones 0.9 Visit Page
95 Sitemap - Hematological Disorders 0.9 Visit Page
96 Sitemap - Immunological and Autoimmune Disorders 0.9 Visit Page
97 Sitemap - Infectious Diseases 0.9 Visit Page
98 Sitemap - Male Health 0.9 Visit Page
99 Sitemap - Musculoskeletal 0.9 Visit Page
100 Sitemap - Neurology 0.9 Visit Page
101 Sitemap - Non-Malignant Disorders 0.9 Visit Page
102 Sitemap - Nutritional Disorders and Weight Loss 0.9 Visit Page
103 Sitemap - Oncology 0.9 Visit Page
104 Sitemap - Ophthalmology 0.9 Visit Page
105 Sitemap - Other Diseases 0.9 Visit Page
106 Sitemap - Otolaryngology 0.9 Visit Page
107 Sitemap - Pediatrics 0.9 Visit Page
108 Sitemap - Rare Diseases 0.9 Visit Page
109 Sitemap - Respiratory Diseases 0.9 Visit Page
110 Sitemap - Sleep Disorders 0.9 Visit Page
111 Sitemap - Toxicology 0.9 Visit Page
112 Sitemap - Womens Health 0.9 Visit Page
113 Sitemap - Medical Devices 0.9 Visit Page
114 Sitemap - Pharmaceutical 0.9 Visit Page
115 Sitemap - Articles 0.9 Visit Page
116 Sitemap - Facts and Figures 0.9 Visit Page
117 Sitemap - Notizia 0.9 Visit Page
118 Sitemap - Others 0.9 Visit Page
119 Sitemap - Snippets 0.9 Visit Page
120 Competitive Landscape of COVID-19 Therapies 0.9 Visit Page
121 Competitive Intelligence Dashboard to Map Market Dynamics 0.8 Visit Page
122 Epidemiology Assessment Case study 0.8 Visit Page
123 Competitive Intelligence Support on few Hematological Malignancies 0.8 Visit Page
124 Immune Checkpoint Inhibitor Market Potential 0.8 Visit Page
125 Oncology Product Assessment Dashboard 0.8 Visit Page
126 ESMO Conference 2021 0.9 Visit Page
127 ESMO 2021 All 0.8 Visit Page
128 Sitemap - Mental Disorders 0.9 Visit Page
129 R&D Landscape Assessment, Manufacturing & Commercial Capabilities 0.8 Visit Page
130 CDMO Competitive Assessment in the USA and Europe 0.8 Visit Page
131 Pipeline Insight 0.8 Visit Page
132 PHARMA CI EUROPE SWISS, 2022 0.9 Visit Page
133 BIO US 2022, THE BIO INTERNATIONAL CONVENTION 0.9 Visit Page
134 ASCO 2022 0.9 Visit Page
135 BIO TRINITY 2022 0.7 Visit Page
136 ASCO Conference 2022 0.9 Visit Page
137 ATS 2022 Conference | ATS Conference Abstracts 0.9 Visit Page
138 ATS 2022 International Conference 0.9 Visit Page
139 Eular 2022 | EULAR 2022 Congress 0.9 Visit Page
140 EULAR 2022 CONFERENCE ABSTRACTS 0.9 Visit Page
141 ATS 2022 INTERNATIONAL CONFERENCE (AMERICAN THORACIC SOCIETY) 0.9 Visit Page
142 EULAR 2022 - ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY 0.8 Visit Page
143 ASCO Conference Abstracts 2022 0.9 Visit Page
144 ESMO 2022 Congress 0.9 Visit Page
145 BIO EUROPE 2022 0.9 Visit Page
146 Festival of Biologics - 2022 0.9 Visit Page
147 Request for Proposal 0.9 Visit Page
148 ESMO 2022 0.9 Visit Page
149 ESMO 2022 Conference | All Abstracts 0.9 Visit Page
150 Consulting Services 0.9 Visit Page
Newsletter/Whitepaper Pages
ID Pages Priority Action
1 Cancer In The United States(Vol 1, Issue 2) 0.8 Visit Page
2 Cancer Globally (Vol. 1, Issue 1) 0.8 Visit Page
3 An Abundance Of Rare 0.8 Visit Page
4 Impact Of BREXIT On Pharma Space 0.8 Visit Page
5 Pompe Disease 0.8 Visit Page
6 Fragile X Syndrome 0.8 Visit Page
7 Complex Regional Pain Syndrome 0.8 Visit Page
8 Cutaneous Lupus Erythematosus 0.8 Visit Page
9 Duchenne Muscular Dystrophy 0.8 Visit Page
10 Gaucher Disease 0.8 Visit Page
11 Generalized Myasthenia Gravis 0.8 Visit Page
12 COVID-19 0.8 Visit Page
13 Let Us Hear From ASCO: Evolution of Precision Medicine 0.8 Visit Page
14 ASCO Reveals: Increasing Options For Relapse/ Refractory Patients In Haematological Malignancies 0.8 Visit Page
15 Fibrodysplasia Ossificans Progressiva 0.8 Visit Page
16 Paroxysmal Nocturnal Hemoglobinuria 0.8 Visit Page
17 Raynaud's Phenomenon 0.8 Visit Page
18 Healthcare Performance Whitepaper 0.8 Visit Page
19 Focal Segmental Glomerulosclerosis 0.8 Visit Page
20 Chronic Inflammatory Demyelinating Polyneuropathy Market 0.8 Visit Page
21 Ataxia Telangiectasia 0.8 Visit Page
22 Retinitis Pigmentosa 0.8 Visit Page
23 Neuroendocrine Tumors 0.8 Visit Page
24 Hereditary ATTR (HATTR) Amyloidosis 0.8 Visit Page
25 Familial Chylomicronemia Syndrome 0.8 Visit Page
26 Hospital-Acquired Bacterial Pneumonia/ Ventilator-Associated Bacterial Pneumonia 0.8 Visit Page
27 Prader-Willi Syndrome 0.8 Visit Page
28 Adult Onset Still's Disease 0.8 Visit Page
29 The Ophthalmic Drug Delivery Therapeutics For Retinal Disorders Whitepaper 0.8 Visit Page
30 Von Hippel-Lindau (VHL) Syndrome 0.8 Visit Page
31 Digital Health Transformation: 2020 Roadmap For Innovation Whitepaper 0.8 Visit Page
32 Exocrine Pancreatic Insufficiency 0.8 Visit Page
33 Warm Autoimmune Hemolytic Anemia 0.8 Visit Page
34 Digital Therapeutics In Mental Health Whitepaper 0.8 Visit Page
35 Car-T Cell Therapy: A Journey From Challenges To Opportunities 0.8 Visit Page
36 The Sanitization Revolution: A Global Powerhouse 0.8 Visit Page
37 Cancer Care In The Time Of COVID 0.8 Visit Page
38 Immune Thrombocytopenic Purpura (ITP) 0.8 Visit Page
39 Herpes Zoster Oticus 0.8 Visit Page
40 Current Treatment Challenges Of IO Refractory Patients And Clinical Development Of Therapies Targeting These Patients 0.8 Visit Page
41 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) 0.8 Visit Page
42 Remdesivir In COVID-19 0.8 Visit Page
43 Progressive Supranuclear Palsy (PSP) 0.8 Visit Page
44 Role Of Artificial Intelligence In Pharma 0.8 Visit Page
45 Pulmonary Arterial Hypertension (PAH) 0.8 Visit Page
46 Biosimilars: Evidence From Europe 0.8 Visit Page
47 Lamellar Ichthyosis 0.8 Visit Page
48 Value-Based Healthcare 0.8 Visit Page
49 Chronic Pancreatitis 0.8 Visit Page
50 Future Of Medical Imaging 0.8 Visit Page
51 Idiopathic pulmonary fibrosis 0.8 Visit Page
52 Real-World Evidence & Diagnostics In Cancer: Filling The Gaps In Oncology Treatment 0.8 Visit Page
53 Soft-Tissue Sarcoma 0.8 Visit Page
54 Induced Pluripotent Stem Cells (IPSCs) Research And Development 0.8 Visit Page
55 Crohn's disease 0.8 Visit Page
56 Role of Traditional Medicine in COVID-19 0.8 Visit Page
57 Alzheimer's disease 0.8 Visit Page
58 Rethinking medtech in Covid times Whitepaper 0.8 Visit Page
59 HIV-Associated Lipodystrophy 0.8 Visit Page
60 Automated Insulin Delivery 0.8 Visit Page
61 Rheumatoid Arthritis 0.8 Visit Page
62 Lean Management: Following the Toyota way in Pharma Industry 0.8 Visit Page
63 Multiple Myeloma 0.8 Visit Page
64 Schizophrenia 0.8 Visit Page
65 Gene Therapy Outlook 2020 0.8 Visit Page
66 Systemic Scleroderma 0.8 Visit Page
67 Anorexia Nervosa 0.8 Visit Page
68 Microneedles: A Smart and Painless Approach of Drug Delivery 0.8 Visit Page
69 Cancer Anorexia 0.8 Visit Page
70 Systemic Lupus Erythematosus (SLE) 0.8 Visit Page
71 Primary Progressive Aphasia (PPA) 0.8 Visit Page
72 Virtual Patients: Role in Future Medications 0.8 Visit Page
73 Lyme Disease 0.8 Visit Page
74 Celiac disease 0.8 Visit Page
75 The Changing face of Consumer Healthcare during COVID-19 0.8 Visit Page
76 Age-Related Macular Degeneration (AMD) 0.8 Visit Page
77 Molluscum Contagiosum 0.8 Visit Page
78 Pyelonephritis 0.8 Visit Page
79 Rise in Utilization of Vitamin and Mineral Supplements 0.8 Visit Page
80 Xerostomia 0.8 Visit Page
81 Osteosarcoma 0.8 Visit Page
82 Methicillin-Resistant Staphylococcus Aureus (MRSA) 0.8 Visit Page
83 Diabetic Macular Edema 0.8 Visit Page
84 Diabetic Retinopathy 0.8 Visit Page
85 Emergence of E-Pharmacies: Changing the world of Pharma Consumerism 0.8 Visit Page
86 Halitosis 0.8 Visit Page
87 Interoperability in Clinical Healthcare 0.8 Visit Page
88 Tinnitus 0.8 Visit Page
89 Cystic Fibrosis 0.8 Visit Page
90 West Nile Disease 0.8 Visit Page
91 Ankylosing Spondylitis 0.8 Visit Page
92 Nestlé vs. Unilever : Strategic Assessment of the two Consumer Giants 0.8 Visit Page
93 Major Depressive Disorder 0.8 Visit Page
94 Atopic Dermatitis 0.8 Visit Page
95 COVID-19: Impact on Pharmaceutical Industry 0.8 Visit Page
96 Atrial fibrillation 0.8 Visit Page
97 Nonalcoholic steatohepatitis (NASH) 0.8 Visit Page
98 CAR T-Cell Therapy 0.8 Visit Page
99 Ulcerative Colitis 0.8 Visit Page
100 Vascular Dementia 0.8 Visit Page
101 Scleroderma 0.8 Visit Page
102 Biosimilar Evidence in the United States 0.8 Visit Page
103 Soft Tissue Sarcoma 0.8 Visit Page
104 Market Intelligence for Pharmaceutical Innovation 0.8 Visit Page
105 Spinal Cord Injury 0.8 Visit Page
106 Atypical Teratoid Rhabdoid Tumors 0.8 Visit Page
107 Wearable Technology in Healthcare 0.8 Visit Page
108 Alopecia Areata 0.8 Visit Page
109 Prostate Cancer 0.8 Visit Page
110 Myelodysplastic Syndrome (MDS) Market Analysis 0.8 Visit Page
111 Chronic Obstructive Pulmonary Disease 0.8 Visit Page
112 Dry Age-related Macular Degeneration 0.8 Visit Page
113 Virtual Clinical Trials 0.8 Visit Page
114 Neuromyelitis Optica Spectrum Disorder 0.8 Visit Page
115 Lupus Nephritis 0.8 Visit Page
116 Cardiovascular Disease Devices Whitepaper 0.8 Visit Page
117 Cocaine Use Disorder 0.8 Visit Page
118 End-Stage Renal Disease 0.8 Visit Page
119 A Multifactorial Evolution of the MedTech Industry Whitepaper 0.8 Visit Page
120 Axial Spondyloarthritis 0.8 Visit Page
121 T cell Lymphoma 0.8 Visit Page
122 Sepsis 0.8 Visit Page
123 Medtronic- A MedTech Success Story 0.8 Visit Page
124 Neurofibromatosis 0.8 Visit Page
125 Gout 0.8 Visit Page
126 A Growing World of Digital Health in the Field of Oncology 0.8 Visit Page
127 Acromegaly 0.8 Visit Page
128 Uremic Pruritusis 0.8 Visit Page
129 Vitiligo 0.8 Visit Page
130 Mergers and Acquisition in MedTech in 2021 0.8 Visit Page
131 Acute Respiratory Distress Syndrome 0.8 Visit Page
132 Peanut Allergy 0.8 Visit Page
133 Cybersecurity of Medical Devices 0.8 Visit Page
134 Wet Age-related Macular Degeneration 0.8 Visit Page
135 Drug discovery to clinical development: Alzheimer’s disease treatment on the verge to change 0.8 Visit Page
136 Medical Marijuana 0.8 Visit Page
137 Chlamydial Infection 0.8 Visit Page
138 mHealth Use in Managing Hemophilia 0.8 Visit Page
139 Thyroid Eye Disease 0.8 Visit Page
140 Postoperative Pain 0.8 Visit Page
141 3-D Bioprinting 0.8 Visit Page
142 Gastroesophageal Reflux Disease 0.8 Visit Page
143 Asthma 0.8 Visit Page
144 AAV Vectors in Gene Therapy 0.8 Visit Page
145 BK Virus Infection 0.8 Visit Page
146 COVID-19: Impact on Pharmaceutical Industry (India) 0.8 Visit Page
147 Intra-Tumoral Cancer Therapies in Melanoma 0.8 Visit Page
148 Developmental and Epileptic Encephalopathy 0.8 Visit Page
149 Technological Trends and Innovation in Dementia Care 0.8 Visit Page
150 Metachromatic Leukodystrophy 0.8 Visit Page
151 Relapsing/Remitting Multiple Sclerosis 0.8 Visit Page
152 PD1-PDL1 inhibitors 0.8 Visit Page
153 Systemic Lupus Erythematosus 0.8 Visit Page
154 RNA Interference 0.8 Visit Page
155 Cachexia 0.8 Visit Page
156 The Changing Face of Cancer Treatment through Novel Biomarkers 0.8 Visit Page
157 Acute Myeloid Leukemia 0.8 Visit Page
158 Toll-like Receptors Agonist 0.8 Visit Page
159 Gene Therapies 0.8 Visit Page
160 Toll-like receptors (TLR) 7 and 8 Agonist 0.8 Visit Page
Conference Profile Pages
ID Pages Priority Action
1 Pfizer’s TALA (talazoparib) in metastatic castration-resistant prostate cancer (mCRPC) 0.8 Visit Page
2 AstraZeneca and Merck’s Lynparza (olaparib) in Metastatic Castration-resistant Prostate Cancer (mCRPC) 0.8 Visit Page
3 Bayer Healthcare and Orion's Nubeqa (darolutamide) in Non-metastatic castration-resistant prostate cancer (nmCRPC) 0.8 Visit Page
4 Roche’s Ipatasertib (RG7440) in Metastatic Castration-resistant Prostate Cancer (mCRPC) 0.8 Visit Page
5 GSK has a strong say in ASCO 2020 as they are announcing key data on Cell Therapy and Next-generation Immuno-oncology 0.8 Visit Page
6 Can much awaited JAVELIN data give any surprise in ASCO 2020? 0.8 Visit Page
7 Another new combination approaches for front line multiple myeloma may bring a new option to patients 0.8 Visit Page
8 How effectively microsatellite instability-high/mismatch repair can be used for proper positioning in the Colorectal Cancer treatment landscape? 0.8 Visit Page
9 Another win for blockbuster Osimertinib (in an early stage of EGFR NSCLC) will further strengthen its potential in Lung Cancer 0.8 Visit Page
10 KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative... 0.8 Visit Page
11 Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)... 0.8 Visit Page
12 PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2... 0.8 Visit Page
13 Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOT... 0.8 Visit Page
14 Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, doubleblinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breas... 0.8 Visit Page
15 A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triplenegative breast cancer (mTNBC) (ENHANCE 1). 0.8 Visit Page
16 Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer. 0.8 Visit Page
17 A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. 0.8 Visit Page
18 SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC)... 0.8 Visit Page
19 Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer. 0.8 Visit Page
20 A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metas... 0.8 Visit Page
21 Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (H... 0.8 Visit Page
22 Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast canc... 0.8 Visit Page
23 Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: (DART=Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors) (SWOG S1609, Cohort 36). 0.8 Visit Page
24 A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlatio... 0.8 Visit Page
25 A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC) 0.8 Visit Page
26 IMvigor130 results might support the usage of combination of atezolizumab +/- platinum/gemcitabine as an important new treatment option for patients with untreated mUC. 0.8 Visit Page
27 Another missed trial of the ASCO 2020 as Adjuvant treatment with the PD-L1 inhibitor did not significantly improve disease-free survival (DFS) in patients with muscle-invasive bladder cancer 0.8 Visit Page
28 Promising results from IMbrave150 TRIAL of Atezolizumab + Bevacizumab may shift the treatment paradigsm for advanced HCC 0.8 Visit Page
29 Good clinical response for dual immune checkpoint inhibitors (Tremelimumab + Durvalumab) in second line HCC however, tough fight ahead in first line setting from much promising Atezolizumab + Bevacizu... 0.8 Visit Page
30 Long term follow up of Lifileucel treatment in a heavily pretreated metastatic melanoma patients who progressed on multiple prior therapies, including anti-PD1 and BRAF/MEK inhibitors 0.8 Visit Page
31 Future directions for Head and Neck treatment based on TMB studies 0.8 Visit Page
32 Long term follow up study of the use of pembrolizumab and its combination as first line treatment for recurrent/metastatic head and neck cancer 0.8 Visit Page
33 Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irino... 0.8 Visit Page
34 Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longerterm follow-up of the phase II, KEYNOTE-164 study. 0.8 Visit Page
35 Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical... 0.8 Visit Page
36 A Phase II, multicenter, open-label study of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer 0.8 Visit Page
37 Interim analysis of ZUMA-5: A phase II study of axi-cel in pts with R/R iNHL 0.8 Visit Page
38 Lisocabtagene maraleucel (liso-cel) for treatment of 2L TNE R/R aggressive large B-cell NHL 0.8 Visit Page
39 Effect of enasidenib plus azacitidine (AZA) on Complete and overall response versus AZA monotherapy in mutant-IDH2 newly diagnosed AML 0.8 Visit Page
40 Tolerability and efficacy of anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML: Phase Ib results 0.8 Visit Page
41 Glasdegib plus low-dose cytarabine in AML or MDS: BRIGHT AML 1003 final report and four-year OS follow-up 0.8 Visit Page
42 Five year results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML 0.8 Visit Page
43 6 month update: Phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with AML (VIALE-C) 0.8 Visit Page
44 Long-term survivors and gilteritinib safety post 1 year in FLT3-mutated R/R AML: ADMIRAL trial 0.8 Visit Page
45 Glasdegib in combination with azacitidine in patients with untreated higher-risk MDS, AML and CMML: Effects on marrow recovery and transfusion independence 0.8 Visit Page
46 CC-486 is safe and well-tolerated as maintenance therapy in patients >75 years with AML in first remission following induction chemotherapy: Phase III QUAZAR AML-001 trial 0.8 Visit Page
47 HRQoL in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with AML in first remission following induction chemotherapy 0.8 Visit Page
48 Venetoclax + intensive chemo with CLIA achieves high rates of durable complete remission with low rates of MRD in pts with newly diagnosed AML 0.8 Visit Page
49 Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk MDS 0.8 Visit Page
50 Phase I study of teclistamab, a dual-targeting immunotherapeutic, in relapse/refractory Multiple Myeloma 0.8 Visit Page
51 Initial results from phase III BOSTON study, comparing weekly selinexor + Vd versus twice weekly Vd in patients with R/R multiple myeloma 0.8 Visit Page
52 Initial KarMMa results : bb2121, a BCMA-targeted CAR T-cell therapy, in R/R multiple myeloma patients 0.8 Visit Page
53 Phase 1/2 update from EVOLVE study : orva-cel, a BCMA- directed CAR T cell therapy for patients with R/R multiple myeloma 0.8 Visit Page
54 Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of antiCD22 activity 0.8 Visit Page
55 Safety and efficacy results of GC027: The first-in-human, universal CART cell therapy for adult r/r T-ALL 0.8 Visit Page
56 Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a BCMA-directed CAR-T-cell therapy, in R/R multiple myeloma 0.8 Visit Page
57 Primary analysis of phase II trial of VRd with/without elotuzumab for newly diagnosed multiple myeloma (SWOG-1211). 0.8 Visit Page
58 Depth of response to isatuximab + KRd (Isa-KRd) in front-line treatment of multiple myeloma: Interim analysis of the GMMG-CONCEPT trial 0.8 Visit Page
59 Updates from BELLINI, a phase III study of venetoclax or placebo in combination with Vd in R/R multiple myeloma 0.8 Visit Page
60 Selinexor, daratumumab, and dexamethasone in patients with R/R multiple myeloma 0.8 Visit Page
61 VRd superiority to lenalidomide, adriamycin, and dexamethasone (RAd) prior to risk-adapted transplant in newly diagnosed myeloma 0.8 Visit Page
62 Phase III TOURMALINE-MM4 : Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma patients not undergoing ASCT 0.8 Visit Page
63 DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with R/R multiple myeloma refractory to PI, IMiD, and anti-CD38 mAb 0.8 Visit Page
64 BELLINI study : Evaluation of MRD in R/R multiple myeloma patients treated with venetoclax or placebo with Vd 0.8 Visit Page
65 DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with Vd in R/R multiple myeloma 0.8 Visit Page
66 First-in-human data of ALLO-501 and ALLO-647 in R/R LBCL/FL: ALPHA study 0.8 Visit Page
67 Comparison of efficacy and safety with obinutuzumab plus chemo vs. rituximab plus chemo in patients with previously untreated FL: Updates from phase III Gallium Study 0.8 Visit Page
68 First-line immunochemotherapy for FL in the GALLIUM study: Prognostic value of PET-CT status after long-term follow-up 0.8 Visit Page
69 Bosutinib for CP-CML after imatinib failure: 8-year update 0.8 Visit Page
70 Independent review: Arterial occlusive events due to ponatinib in PACE trial Ph+ CML 0.8 Visit Page
71 Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analyses from the BYOND study 0.8 Visit Page
72 KEYNOTE-204: Phase III study of Pembrolizumab vs Brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma 0.8 Visit Page
73 HALO Trial: Brentuximab vedotin and bendamustine as first-line treatment of Hodgkin lymphoma in the elderly 0.8 Visit Page
74 Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients. 0.8 Visit Page
75 Gls-010 in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Impressive Phase II Results 0.8 Visit Page
76 Long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell NHL and CLL 0.8 Visit Page
77 Safety and efficacy of optimized tandem CD19/CD20 CAR-engineered T cells in patients with R/R NHL 0.8 Visit Page
78 Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL 0.8 Visit Page
79 Phase I study of AUTO3 with pembrolizumab in patients with r/r DLBCL 0.8 Visit Page
80 Epcoritamab (GEN3013) to induce CR in pts with R/R B-NHL: Complete dose escalation data and efficacy results from a phase I/II trial 0.8 Visit Page
81 Retreatment of pts with refractory DLBCL with axi-cel in ZUMA-1 0.8 Visit Page
82 Final results of Lenalidomide plus R-GDP (R2-GDP) - GOTEL in relapsed/refractory diffuse large B-cell lymphoma 0.8 Visit Page
83 RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy in transplant-ineligible pts with R/R DLBCL 0.8 Visit Page
84 Outpatient treatment with liso-cel across a variety of clinical sites from three ongoing clinical studies in R/R LBCL. 0.8 Visit Page
85 Atezolizumab + obinutuzumab + venetoclax in patients with R/R DLBCL: Primary analysis of a phase II trial from LYSA 0.8 Visit Page
86 Finally Opdivo in combination with Yervoy has got success in much awaited lucrative first line NSCLC patients whose tumors express PD-L1≥1% and approval is further supported by long term data 0.8 Visit Page
87 Wthin a space of 11 days, Opdivo-Yervoy with chemo bagged another approval in first line NSCLC irrespective of PD-L1 expression 0.8 Visit Page
88 Frontline durvalumab and tremelimumab combo misses overal survival endpoint in metastatic NSCLC 0.8 Visit Page
89 Another new combination of tiragolumab and atezolizumab has shown efficacy signals in lucrative first line NSCLC 0.8 Visit Page
90 Novartis unveils more capmatinib data from GEOMETRY mono-1 study 0.8 Visit Page
91 Osimertinib trial results in NSCLC patients with EGFR exon 20 insertions from ECOG-ACRIN 5162 trial 0.8 Visit Page
92 Roche presented long term data of alectinib from ALEX study in frontline advanced ALK+ NSCLC 0.8 Visit Page
93 Another MET inhibitor expected to make their way in METex14+ mutated NSCLC 0.8 Visit Page
94 Novartis presented the data from GEOMETRY mono-1 study to support the capmatinib usage in second line setting 0.8 Visit Page
95 Takeda published brigatinib data from J-ALTA study to supprt its approval in Japanese patients 0.8 Visit Page
96 Heat Biologics's allogeneic cellular vaccine in combination with nivolumab shown efficacy signals in phase I/II data 0.8 Visit Page
97 Pembrolizumab usage along with radiothreapy associated with better efficacy outcomes 0.8 Visit Page
98 Merck presented the data from VISION study to support its FDA approval in patients with NSCLC with METex14 skipping 0.8 Visit Page
99 Two year follow up data of bintrafusp alfa presented by Merck with encouraging efficacy signals 0.8 Visit Page
100 CheckMate 568 Part 2 data will further support the approval of nivolumab plus ipilimumab with two cycles of chemotherapy combo in firstline NSCLC setting 0.8 Visit Page
101 Pegilodecakin did not show any improvement in efficacy when added to pembrolizumab in first line NSCLC 0.8 Visit Page
102 Data from exploratory RELAY+ study of ramucirumab plus gefitinib supports its usage in first line EGFR mutated NSCLC 0.8 Visit Page
103 Phase II study of venetoclax plus dose-adjusted R-EPOCH for Richter’s syndrome 0.8 Visit Page
104 Good interim data from phase 2 trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC 0.8 Visit Page
105 Initial results of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax 0.8 Visit Page
106 Novartis presented Phase II data of one more promising irreversible 3rd-generation EGFR TKI 0.8 Visit Page
107 TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions 0.8 Visit Page
108 Acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL: ASCEND final results 0.8 Visit Page
109 Final data of KEYNOTE-189 study in patients with newly diagnosed metastatic nonsquamous NSCLC 0.8 Visit Page
110 Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib + trametinib in patients with BRAF V600E mutant metastatic NSCLC 0.8 Visit Page
111 Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC 0.8 Visit Page
112 Effect of adding ublituximab to ibrutinib on efficacy in previously treated high-risk CLL: GENUINE phase III study 0.8 Visit Page
113 Some supporting data of Lorlatinib; irreversible 3rd-generation EGFR TKI in patients with ALK-positive NSCLC 0.8 Visit Page
114 Mute response of Durvalumab trial as Durvalumab plus tremelimumab fails to show the clinical activity in patients with acquired resistance to PD-1 checkpoint inhibitors 0.8 Visit Page
115 Acalabrutinib in treatment-naïve CLL: Mature results from Ph II study demonstrating durable remissions and longterm tolerability 0.8 Visit Page
116 Fixed-duration venetoclax-obinutuzumab for previously untreated pts with CLL: Follow-up results from phase III CLL14 trial 0.8 Visit Page
117 Supportive data from Nivolumab trial for its use as monotherapy or in combination with cisplatin/carboplatin and etoposide as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC) 0.8 Visit Page
118 Phase III MURANO study results: Impact of premature venetoclax discontinuation/interruption on outcomes in R/R CLL 0.8 Visit Page
119 Consistent result of tazemetostat in terms of Efficacy, safety, and immune priming effect in patients with epithelioid sarcoma. 0.8 Visit Page
120 Eribulin and pembrolizumab disappointed with its efficacy results in Uterine leiomyosarcoma (LMS) 0.8 Visit Page
121 Role of CDK4/6 inhibitors in treating advanced Soft Tissue Sarcoma (STS) 0.8 Visit Page
122 Highest reported efficacy of doxorubicin + pembrolizumab till date in a preliminary advanced STS trial 0.8 Visit Page
123 AKT inhibition by Ipatasertib in mCRPC: The A.MARTIN Randomized Phase II trial 0.8 Visit Page
124 Updated results from ARAMIS phase III trial showed darolutamide improves overall survival (OS) over placebo in nmCRPC patients 0.8 Visit Page
125 Updated overall survival results from PROSPER: A phase III, randomized, double-blind, placebo controlled study of enzalutamide (ENZA) in men with nmCRPC 0.8 Visit Page
126 Apalutamide Plus ADT Leads to Significantly Improved Outcomes in Nonmetastatic CRPC: Results from the phase III SPARTAN trial 0.8 Visit Page
127 Novel AKT inhibitor fails to demonstrate a difference in the primary outcome of PFS: Results from phase II ProCAID trial 0.8 Visit Page
128 Pembrolizumab plus enzalutamide in patients with abiraterone acetate pretreated mCRPC: KEYNOTE-365 cohort C efficacy, safety, and biomarker results 0.8 Visit Page
129 HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer 0.8 Visit Page
130 Impact of Olaparib vs Physician’s Choice of New Hormonal Agent On Burden of Pain in mCRPC: Results from PROfound 0.8 Visit Page
131 AstraZeneca presented the Health-related quality of life (HRQoL) data for olaparib versus enzalutamide or abiraterone in mCRPC with HRR gene alterations 0.8 Visit Page
132 Exelixis reports data from Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With mCRPC 0.8 Visit Page
133 Pfizer has presented the positive interim data of PARP inhibitor from the TALAPRO-1 phase II trial 0.8 Visit Page
134 Data from CARD study Confirm Benefit of Cabazitaxel Over Abiraterone or Enzalutamide in mCRPC 0.8 Visit Page
135 Much awaited result of Trastuzumab + trimodality treatment for HER2+ esophageal adenocarcinoma brought disappointment with its failure in reaching the primary end point 0.8 Visit Page
136 No significant survival benefit of pembrolizumab over 2L paclitaxel in previusly treated PD-L1+ advanced gastric or gastroesophageal junction cancer 0.8 Visit Page
137 Tumor mutational burden (TMB) demonstrates a positive association with clinical outcomes with pembrolizumab in gastric cancer 0.8 Visit Page
138 Another PD-1 inhibitor (Sintilimab) jointly developed by Innovent and Eli Lilly has met its primary endpoint of overall survival in the second-line treatment of patients with metastatic esophageal squ... 0.8 Visit Page
139 In gastric cancer no treatment till date has shown such a strong data, Definately Enhetru will be positioned much ahead of Kadcyla 0.8 Visit Page
140 A rare failure of Olaparib brought a lot of disappointment for ovarian cancer patient community 0.8 Visit Page
141 Role of DOCK8, EP 400, and PDX1 mutations as prognostic biomarkers & its association with longer survival in patients treated with Selinexor. 0.8 Visit Page
142 Role of MDNA55 (Interleukin-4 Receptor) in a difficult to treat population (de novo GBM, IDH wild-type, not eligible for surgery at recurrence) & its benefit for patient resistant to temozolomide. 0.8 Visit Page
143 Another novel combination approach (INO-5401 + INO-9012 with Cemiplimab) for newly diagnosed GBM patients 0.8 Visit Page
144 Not so encouraging results for Atezolizumab in comination of Temozolomide for newly diagnosed GBM 0.8 Visit Page
145 Savolitinib can be a better treatment choice than sunitinib due to its improved efficacy and safety profile 0.8 Visit Page
146 Results from TIVO-3 supports use of Tivozanib for highly treatment refractory RCC patients 0.8 Visit Page
147 Not very promising but Cabozantinib is an effective treatment option for the patients with advanced refractory RCC 0.8 Visit Page
148 The result from KEYNOTE-426 warrants the use of pembrolizumab and axitinib as a standard of care for patients with previously untreated RCC 0.8 Visit Page
149 Lenvatinib plus Pembrolizumab shows strong data for mccRCC with disease progression following prior PD-1/PDL-1 therapy 0.8 Visit Page
150 Tumor Mutation Burden (TMB): One Size fits for all? Not really! 0.8 Visit Page
151 Lilly overthrows Pfizer in Early HR+/HER2- Breast Cancer, what Next? 0.8 Visit Page
152 ESMO 2020 – Major trials in focus and Our View Points 0.8 Visit Page
153 Triumphs and Troubles for Combination Therapies in Melanoma: COMBI-I Trial Failure Story 0.8 Visit Page
154 Will ADC’s be in focus in ESMO 2020 too? 0.8 Visit Page
155 BMS/Exelixis face-off with Merck’s Keytruda in front-line renal cancer 0.8 Visit Page
156 Gilead's ASCENT into Oncology: Sacituzumab results at ESMO 2020 0.8 Visit Page
157 ADAURA trial results presented at ESMO established proven clinical activity of Tagrisso (osimertinib) in the adjuvant treatment of early-stage EGFR-mutated lung cancer (EGFRm) 0.8 Visit Page
158 ASCENT trial results establish Sacituzumab as new standard of care in third line for metastatic TNBC 0.8 Visit Page
159 Promising results from the CROWN trial supports Lorbrena (lorlatinib) as a future first-line standard treatment in ALK+ NSCLC 0.8 Visit Page
160 ESMO 2020: CheckMate 9ER Provides New First-Line Treatment Option for Patients Advanced RCC 0.8 Visit Page
161 Head & Neck Cancers ESMO 2020 Insights 0.8 Visit Page
162 Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatc... 0.8 Visit Page
163 Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study 0.8 Visit Page
164 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter,... 0.8 Visit Page
165 Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer 0.8 Visit Page
166 Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2- negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 random... 0.8 Visit Page
167 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) adva... 0.8 Visit Page
168 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer 0.8 Visit Page
169 nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer 0.8 Visit Page
170 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic tripl... 0.8 Visit Page
171 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative bre... 0.8 Visit Page
172 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC) 0.8 Visit Page
173 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase... 0.8 Visit Page
174 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of th... 0.8 Visit Page
175 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004 0.8 Visit Page
176 Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238 0.8 Visit Page
177 Estimating long-term survivorship in patients with advanced melanoma treated with immune-checkpoint inhibitors: Analyses from the phase III CheckMate 067 trial 0.8 Visit Page
178 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study) 0.8 Visit Page
179 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours 0.8 Visit Page
180 Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib) 0.8 Visit Page
181 Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC 0.8 Visit Page
182 Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO-292) 0.8 Visit Page
183 POD1UM-201: A phase II study of retifanlimab (INCMGA00012) in advanced or metastatic Merkel cell carcinoma (MCC) 0.8 Visit Page
184 Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL 0.8 Visit Page
185 Phase 2 Trial of Lenvatinib + Pembrolizumab for Progressive Disease After PD-1/PD-L1 Immune Checkpoint Inhibitor in Metastatic Clear Cell Renal Cell Carcinoma: Results by Independent Imaging Review an... 0.8 Visit Page
186 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease 0.8 Visit Page
187 A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic u... 0.8 Visit Page
188 Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell c... 0.8 Visit Page
189 Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma... 0.8 Visit Page
190 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial 0.8 Visit Page
191 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI) 0.8 Visit Page
192 Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study 0.8 Visit Page
193 Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastriccancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First result... 0.8 Visit Page
194 Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study 0.8 Visit Page
195 EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% 0.8 Visit Page
196 Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homol... 0.8 Visit Page
197 HR+/HER2- Breast Cancer ESMO 2020 Insights 0.8 Visit Page
198 PROfound Phase III trial results presented at ESMO established proven clinical activity of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 or ATM g... 0.8 Visit Page
199 Highlights in Urothelial Carcinoma- ESMO 2020 0.8 Visit Page
200 ESMO 2020: Best of GI Cancers 0.8 Visit Page
201 COSMIC-021: Another exceptional findings by Exelixis after the success of CheckMate -9ER study results 0.8 Visit Page
202 ESMO 2020 – Ovarian Cancer Highlights 0.8 Visit Page
203 ASCO 2021 Preview - Showstoppers in Gastric Cancers 0.8 Visit Page
204 Amgen and Mirati – Leading Players With High Hopes for the Undruggable KRAS Mutation? 0.8 Visit Page
205 We Have Got You Covered – Major Data Readouts at ASCO 2021 Annual Meeting 0.8 Visit Page
206 ASC0 2021 Preview: Opdivo Boosting Relatlimab (LAG-3 Immunotherapy) Expected to Steal the Show? 0.8 Visit Page
207 Triumph of Trop-2 in Antibody-Drug Conjugate (ADC) Space 0.8 Visit Page
208 ASCO 2021 – MAGE-A4: Expectations from one of the most promising target in Oncology 0.8 Visit Page
209 ASCO 2021-OlympiA Trial: Label Expansion of Lynparza Could Open New Commercial Opportunities 0.8 Visit Page
210 Antibody Drug Conjugates Market Expansion: Steady Foothold in Cancer Treatment Through Significant Pacts 0.8 Visit Page
211 Novartis’ Phase III VISION Study: Radio-ligand Therapy Heading for Regulatory Approval 0.8 Visit Page
212 Day 1: ASCO 2021 Bladder Cancer Highlights 0.8 Visit Page
213 Day 1: ASCO 2021 Cholangiocarcinoma Highlights 0.8 Visit Page
214 Day 1 Highlights from Renal Cell Carcinoma (RCC) – ASCO 2021 0.8 Visit Page
215 Day 1 Highlights in Sarcoma - ASCO 2021 0.8 Visit Page
216 Day 1- ASCO 2021: Esophageal-Squamous Cell Carcinoma Highlights 0.8 Visit Page
217 Day 1 Highlights in Breast Cancer- ASCO 2021 (Local/Regional/Adjuvant) 0.8 Visit Page
218 Day 1 Highlights in Pancreatic Cancer- ASCO 2021 0.8 Visit Page
219 Day 1 Highlights from Lung cancer - ASCO 2021 0.8 Visit Page
220 Day 1 Highlights from Hematological cancer - ASCO 2021 0.8 Visit Page
221 Day 2 Highlights in Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer- ASCO 2021 0.8 Visit Page
222 Day 1-2 Highlights from Head and Neck Cancer (HNSCC) – ASCO 2021 0.8 Visit Page
223 Day 1-2 ASCO 2021 Colorectal Cancer Highlights 0.8 Visit Page
224 Day 2 Highlights in Breast Cancer- ASCO 2021 0.8 Visit Page
225 Day 2 Highlights from Hematological cancer – ASCO 2021 0.8 Visit Page
226 Day 3 Nasopharyngeal Carcinoma Highlights ASCO21 0.8 Visit Page
227 Day 3 Glioblastoma Multiforme (GBM) - ASCO 2021 Highlights 0.8 Visit Page
228 Day 3 Highlights from Lung cancer - ASCO 2021 0.8 Visit Page
229 Day 3 RCC Highlights ASCO 2021 0.8 Visit Page
230 ASCO 2021: Spotlight on Major Abstract in the Melanoma Segment 0.8 Visit Page
231 Day 4 Highlights from Prostate Cancer - ASCO 2021 0.8 Visit Page
232 Day 4 Highlights from Hematological Cancers - ASCO 2021 0.8 Visit Page
233 Day 4 Highlights-Gynecological Cancer- ASCO 2021 0.8 Visit Page
234 Day 4- Nasopharyngeal cancer (NPC) Highlights: ASCO 2021 0.8 Visit Page
235 Day 4 - Colorectal Cancer ASCO 2021 Highlights 0.8 Visit Page
236 Thyroid Cancer Highlights - ASCO 2021 0.8 Visit Page
237 Highlights from Melanoma - ASCO 2021 0.8 Visit Page
238 ESMO 2021 Preview: Margenza—a breast cancer drug—sets its niche in HER2 positive Gastric Cancer Space 0.8 Visit Page
239 ESMO 2021 Preview: Lilly and Innovent’s Sintilimab all set to present its high phase results in Esophageal Squamous Cell Cancer and Gastroesophageal Adenocarcinoma 0.8 Visit Page
240 Cheers to new headways in Oncology: Are you all ready for ESMO 2021 Annual Meeting? 0.8 Visit Page
241 ESMO 2021 Preview: Merck now Moving Ahead with Welireg and Cabozantinib Combination in Advanced ccRCC, Post-Welireg’s Speedy Approval in VHL-associated RCC 0.8 Visit Page
242 KRAS Players in ESMO 2021 – Mirati’s Adagrasib expected to Knockout Amgen’s much-hyped Lumakras in Colorectal Cancer: Can Toxicity Issues Ruin Mirati’s Plan? 0.8 Visit Page
243 ESMO 2021 Preview: Daiichi and AstraZeneca’s Antibody Drug Conjugate (ADC) in advanced NSCLC 0.8 Visit Page
244 ESMO 2021 Preview: Keytruda, already approved as a second-line treatment in Cervical Cancer, now eyeing first line setting 0.8 Visit Page
245 Abstract LBA1: DS-8201– keeping up with a continuous need for newer options and better outcomes for Breast Cancer patients 0.8 Visit Page
246 Bristol Myers Squibb to disclose data on Checkmate-651 trial evaluating Opdivo and Yervoy combination in frontline SCCHN after the regimen surprisingly fails to meet the primary endpoint 0.8 Visit Page
247 Merck to present overall survival results from KEYNOTE-355 in frontline Triple-Negative Breast Cancer to further support accelerated approval received in late 2020 0.8 Visit Page
248 Evolving Landscape in First-Line HER2+ gastric cancer and gastro esophageal junction (GEJ) cancer 0.8 Visit Page
249 ESMO 2021: Leap Therapeutics flags the potential in advanced first-line Gastroesophageal adenocarcinoma (GEA) 0.8 Visit Page
250 ESMO 2021: Promising results of Ayala Pharma’s AL101 in Phase II ACCURACY trial for a rare form of cancer, Adenoid Cystic Carcinoma (ACC) 0.8 Visit Page
251 ESMO 2021: Gritstone to advance its Neo-antigen Immunotherapy in Phase II/III metastatic, microsatellite-stable (MSS)-Colorectal Cancer (CC) 0.8 Visit Page
252 ESMO 2021 Highlights: Sneak peek into some early phase results of Lung, Pancreatic, Prostate Cancer and others 0.8 Visit Page
253 ESMO 2021: Merck provides first glimpse of combination activity of belzutifan and cabozantinib in advanced clear cell renal cell carcinoma (ccRCC). 0.8 Visit Page
254 Merck’s Keytruda already carrying cervical cancer label in second-line, now spells a win in front-line setting with or without Avastin 0.8 Visit Page
255 ZENITH20 (LBA46) Phase II trial shows positive results with Poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations 0.8 Visit Page
256 ESMO 2021 Lung Cancer Highlights: Onboarding of Libtayo-Chemotherapy combo in first-line NSCLC. Should Merck worry? 0.8 Visit Page
257 Glad tidings for the Chinese Biopharmaceuticals in the Gastro-intestinal (GI) cancer 0.8 Visit Page
258 ESMO 2021: Post Tivdak’s successful approval in second line cervical cancer, the ADC now heading towards first-line setting as combination regimen 0.8 Visit Page
259 ESMO 2021: Daiichi and AstraZeneca’s Antibody Drug Conjugates (ADCs) in early phase trials, post Enhertu’s outstanding success in breast cancer 0.8 Visit Page
260 BMS’ LAG-3 and PD-1 inhibitor combo all set to fulfill high hopes in melanoma, post receiving priority review by the FDA 0.8 Visit Page
261 Already approved as an adjuvant therapy in late stage melanoma, Merck’s Keytruda is now eyeing completely resected high-risk stage II melanoma patients (KEYNOTE-716) 0.8 Visit Page
262 Exelixis excited to receive Cabometyx’s approval in radioiodine-refractory differentiated thyroid cancer (DTC) 0.8 Visit Page
263 ASCO 2022: A Quick preview of Late-Breaking Abstracts (LBA) on Lung Cancer. Let’s not miss it! 0.8 Visit Page
264 ASCO 2022 Preview Content for Breast Cancer 0.8 Visit Page
265 ASCO 2022 Preview: Prostate Cancer 0.8 Visit Page
266 ASCO 2022 Preview: Follicular Lymphoma 0.8 Visit Page
267 ASCO 2022: A quick preview of key abstract on melanoma. Let’s not miss it! 0.8 Visit Page
268 ASCO 2022: A Quick preview on Diffuse large B-cell lymphoma (DLBCL) 0.8 Visit Page
269 ASCO 2022 PREVIEW: GYNECOLOGIC CANCER 0.8 Visit Page
270 Cullinan Oncology’s CLN-081 demonstrates encouraging response in NSCLC patients with EGFR Exon 20 Insertion Mutations. 0.8 Visit Page
271 Immutep's next-generation immunotherapy performs well in first-line NSCLC, offering some relief following the recent failure of the novel anti-TIGIT in lung cancer. 0.8 Visit Page
272 Mirati’s Adagrasib overthrows Amgen’s Sotorasib and yielded a response rate of 43% in KRAS G12C mutation mNSCLC. Do first-mover advantage and safety give an edge to Sotorasib? 0.8 Visit Page
273 Exelixis’ flagship product Cabozantinib demonstrated an ORR of 54% with 91% clinical benefit in Head and Neck Squamous Cell Carcinoma 0.8 Visit Page
274 Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows durable responses in R/R DLBCL in a pivotal phase II trial. Can Epcoritamab beat the CR rate of 39%? 0.8 Visit Page
275 Braftovi shows a higher response rate in a triplet combination after adding Opdivo. Shifting focus towards microsatellite stable metastatic colorectal cancer (MSS CRC) patients. 0.8 Visit Page
276 Closely watched Janssen and Legend Biotech's CAR-T cell therapy demonstrated durable responses in the earlier setting of Multiple Myeloma: Updated findings from the CARTITUDE-2 trial. 0.8 Visit Page
277 Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients with R/R follicular lymphoma (FL). Could safety issues be a concern? 0.8 Visit Page
278 Gilead in trouble waters as Trodelvy shows below par response in 3L+ HR+/HER2- Breast Cancer Setting. Likelihood of a delayed launch and reduced market share? 0.8 Visit Page
279 Daiichi’s Patritumab, its third ADC making headway in HER3 expressing metastatic Breast Cancer 0.8 Visit Page
280 Enhertu carving out a new space for itself in HER2 low patients. A major-label expansion is likely on the way. 0.8 Visit Page
281 Yet another failure in treating Small-Cell Lung Cancer as Roche's much-anticipated anti-TIGIT immunotherapy fails in Phase III 0.8 Visit Page
282 Consistent results across all sub-groups seen in the newly launched first in class LAG-3 combination drug Opdualag 0.8 Visit Page
283 Encouraging results of nivolumab + bevacizumab + FOLFOXIRI in patients with RAS/BRAF mutations as a 1st Line treatment option, Opportunity for BMS for further expanding its blockbuster label for CRC p... 0.8 Visit Page
284 Merus’ Zenocutuzumab, a HER2-HER3 Bispecific Antibody, Successfully Targets NRG1 Fusions in Lung and Pancreatic Cancer 0.8 Visit Page
285 Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in Multiple Myeloma during ASCO 2022. 0.8 Visit Page
286 Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-line setting for the patients with R/R Large B-cell lymphoma (LBCL)? 0.8 Visit Page
287 The PROs further support Durvalumab + Chemo in becoming the new standard of care in 1st Line Advanced Biliary Tract Cancer, patients with high treatment unmet needs. 0.8 Visit Page
288 Takeda’s flagship product panitumumab (PAN) + mFOLFOX6 versus bevacizumab (BEV) + mFOLFOX6 demonstrated better outcomes in primary endpoints for the Left-sided tumor population in metastatic colorecta... 0.8 Visit Page
289 Making way for immunotherapy in the GI cancers, Durvalumab to become the new standard of care for advanced biliary tract cancers 0.8 Visit Page
290 With modest efficacy, Neratinib continues to be a potential treatment option for HER2+ive biliary tract cancers. Puma Biotech to continue its search for more effective combination therapies. 0.8 Visit Page
291 Is there enough opportunity in the competitive therapeutic landscape of Multiple Myeloma for new CAR-T cell therapies? Let's have a look at the promising results of early-stage CAR-T cell therapy pres... 0.8 Visit Page
292 AbbVie’s telisotuzumab vedotin (Teliso-V) demonstrated encouraging responses in c-MET NSCLC patients who progressed on previous treatments. 0.8 Visit Page
293 Daiichi’s novel HER3 ADC has shown to have a spark in HER3 NSCLC, post success in HER3 Breast Cancer trial. 0.8 Visit Page
294 Junshi’s domestic Toripalimab’s significant results in recurrent or metastatic HNSCC. CRL issued on Nasopharyngeal Carcinoma could prove to be a setback? 0.8 Visit Page
295 Sermonix’s Lasofoxifene, a potent oral SERM, emerges as a critical player in ESR1 mutated advanced HR+ breast cancer 0.8 Visit Page
296 Mimivax’s SurVaxM improves survival time in newly diagnosed glioblastoma. A ray of hope flickers in deadly cancer. 0.8 Visit Page
297 Novartis’s Tafinlar and Mekinist’s combo might receive a first-mover advantage in BRAF mutated Low-grade glioma. 0.8 Visit Page
298 Is Paxalisib better than Temozolomide in the first-line setting? Approval seems quite challenging, though. 0.8 Visit Page
299 With the emergence of Next-generation SERDs, Sanofi might hit the mark; however, competition seems tough 0.8 Visit Page
300 Elranatamab exhibits a 60.6% ORR and a tolerable safety profile, according to new results from a planned interim analysis of the Phase II MagnetisMM-3 registration-enabling study. 0.8 Visit Page
301 Sanofi’s ADC is targeting CEACAM5 in patients with NSCLC. CEACAM5 is expressed in 20% of patients with NSCLC adenocarcinoma. 0.8 Visit Page
302 Performance of Veru Pharma’s Sabizabulin in Phase I/II mCRPC trial. Phase III VERACITY trial has already commenced. 0.8 Visit Page
303 Is GSK's Jemperli giving hope that cancer can be cured? 100% Response rate is unbelievable. 0.8 Visit Page
304 CEL-SCI Corporation presents first of its kind results for lower-risk advanced primary SCCHN population in 25+ years through its Phase III IT-MATTERS study. 0.8 Visit Page
305 Rocky road for Next-generation SERDs and Dominance of Verzenio in Adjuvant Setting: ER+/HER2− Early Stage Breast Cancer Insights 0.8 Visit Page
306 ESMO 2022 Preview: Metastatic Castration Resistant Prostate Cancer (mCRPC) 0.8 Visit Page
307 Early stage results of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma 0.8 Visit Page
308 AmMax Bio’s AMB-05X shows an optimal balance of safety and efficay in TSGCT patients 0.8 Visit Page
309 Derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 mutations. 0.8 Visit Page
310 Already established combination in refractory mCRC patients to show results in the front-line patients to capture market share 0.8 Visit Page
311 Do tucatinib and trastuzumab have the potential to get the first mover advantage in HER2 positive mCRC? 0.8 Visit Page
312 Can fruquintinib prove to be more beneficial than the best supportive care in colorectal cancer? 0.8 Visit Page
313 AstraZeneca’s Triplet regimen (durvalumab + Olaparib + Bevacizumab) elicits excellent efficacy profile than doublet (olaparib plus durvalumab) in non gBRCA mutated (wild type), platinum-sensitive ovar... 0.8 Visit Page
314 Clinical study evaluating intermittent relacorilant with nab-paclitaxel in pretreated ovarian cancer 0.8 Visit Page
315 Postmarking clinical assessment of rucaparib vs. chemotherapy in advanced, relapsed patients with deleterious BRCA1/2 mutation in ovarian cancer 0.8 Visit Page
316 Extended follow-up results of Phase I/II study of DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) in patients with advanced solid tumors (Lung Cancer, Esophageal Cancer, and Prostate Cancer) 0.8 Visit Page
317 Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation from the KRYSTAL-1 study 0.8 Visit Page
318 Amgen is attempting to expand into the CRC market with a cocktail of LUMAKRAS and VECTIBIX, however prior evidence indicates liver toxicity signals in Lung Cancer 0.8 Visit Page
319 Beyond Adagrasib and Lumakras, Roche's GDC-6036's phase I data are also scheduled to be presented at ESMO 2022. 0.8 Visit Page
320 Interim analysis of Phase III trial of Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2) 0.8 Visit Page
321 Verzenio, an Eli Lilly CDK4/6 inhibitor, missed the statistical significance in the second interim overall survival analysis, but exhibited a favorable trend; all eyes are now on the final OS analysis... 0.8 Visit Page
322 Data from the planned second interim overall survival (OS) analysis further support Trodelvy (sacituzumab govitecan) in HR+/HER2– metastatic breast cancer 0.8 Visit Page
323 Confirmatory clinical OS results raising questions about the use of rucaparib in advanced Ovarian Cancer 0.8 Visit Page
324 Safety and efficacy results for Phase III trial of a dual anti-HER2 regimen of pyrotinib plus trastuzumab and docetaxel compared with placebo plus trastuzumab and docetaxel in untreated HER2-positive... 0.8 Visit Page
325 The combination of nivolumab with or without ipilimumab in R/M cervical cancer showed encouraging safety and efficacy results 0.8 Visit Page
326 Efficacy results from Phase II (FIDES-01) study with FGFR2F or FGFRMA patients with advanced iCCA with A, ≥1 prior chemotherapy 0.8 Visit Page
327 A Groundbreaking Study in Head and Neck Cancer to Improve Cure Rate by Adding new Treatment to SoC 0.8 Visit Page
328 Talimogene laherparepvec (T-VEC) as neoadjuvant treatment plus surgery vs immediate surgery in patients with resectable stage IVM1a melanoma 0.8 Visit Page
329 Naporafenib (LXH-254) combinations prove to exhibit favorable efficacy with a tolerable safety profile in NRAS-Mutant Unresectable/Metastatic Melanoma 0.8 Visit Page
330 Clinical efficacy and safety analysis update of intermittent relacorilant with nab-paclitaxel in heavily pretreated ovarian cancer patients 0.8 Visit Page
331 Cemiplimab in comparison with Investigator’s choice (IC) of chemotherapy in recurrent/metastatic cervical carcinoma 0.8 Visit Page
332 AstraZeneca’s Triplet regimen (durvalumab + Olaparib + Bevacizumab) bested over olaparib plus durvalumab doublet regimen in critical clinical profile evaluation in ovarian cancer 0.8 Visit Page
333 Adjuvant setting in RCC is a hard nut to crack, nivolumab + ipilimumab combo fails, whereas Keytruda leads 0.8 Visit Page
334 Trastuzumab Deruxtecan (Enhertu), the first US FDA-authorized HER2-directed treatment, produces clinically significant tumor response in patients with HER2m NSCLC in the Phase II DESTINY-Lung02 study 0.8 Visit Page
335 MEDI5752 plus chemotherapy doubled the duration of response among patients with treatment-naïve non-squamous NSCLC, according to findings from a phase Ib/II study 0.8 Visit Page
336 The Keynote-412 trial displays statistically insignificant results for Pembrolizumab plus CRT in locally advanced head and neck squamous cell carcinoma 0.8 Visit Page
337 Closely watched Lynparza, the first PARP inhibitor to enter the first-line metastatic castration-resistant Prostate Cancer (mCRPC) setting demonstrated superior clinical benefit over abiraterone alone 0.8 Visit Page
338 Triplet combination of tremelimumab + durvalumab + chemotherapy (T + D + CT) generated long-term overall survival (OS) benefit in frontline patients with metastatic NSCLC 0.8 Visit Page
339 Preliminary Phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients 0.8 Visit Page
340 Initial results from the INSIGHT 2 study evaluating Tepotinib plus Osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib 0.8 Visit Page
341 Results from the randomized Phase II study of amcenestrant versus endocrine treatment of physician’s choice in patients with endocrine-resistant ER+/HER2− advanced breast cancer (AMEERA-3) 0.8 Visit Page
342 Already established combination in refractory mCRC patients to show results in the front-line patients to capture market share 0.8 Visit Page
343 Data from Phase III CodeBreak200 study showed superior PFS of Lumakras over docetaxel in previously treated non-small cell lung cancer (NSCLC) patients 0.8 Visit Page
344 A promising option for refractory patients expressing HER2+ tucatinib and trastuzumab have the potential to get the first mover advantage in mCRC 0.8 Visit Page
345 FRESCO-2 is a global Phase III study evaluating the safety and efficacy of fruquintinib in heavily pretreated mCRC patients 0.8 Visit Page
346 The clinical results of the DeFi trial of nirogacestat excels in adults with progressing desmoid tumors 0.8 Visit Page
347 Initial Findings from the Phase II/III Trial of AL102 for Desmoid Tumor treatment (DT) 0.8 Visit Page
348 Phase II Study of Belzutifan plus Cabozantinib as First-line Treatment of Advanced Renal Cell Carcinoma (RCC): Cohort 1 of LITESPARK-003 0.8 Visit Page
All Conference Profile Pages
ID Pages Priority Action
1 ATS Conference 0.8 See Artciles
2 Eular Conference 0.8 See Artciles
Blog industries
ID Pages Priority Action
1 Medical Devices 0.8 See Artciles
2 Pharmaceutical 0.8 See Artciles